Please assess the completion status of the following clinical trial:

Trial Title: Regulatory Post-Marketing Surveillance Study for TETRAXIM™

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are 2 months or more of age (as indicated in the currently approved local product labeling) and who are given the study vaccine at least one dose or more, during a routine health-care visit, as primary immunization or booster immunization for the prevention of diphtheria, tetanus, pertussis, poliomyelitis.~* Written informed consent obtained from the subject's parents/legal representative.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- TETRAXIM™ vaccine (Type: EXPERIMENTAL): Participants will receive a primary or booster dose of TETRAXIM™

Based on this trial design, predict the completion outcome and termination type (if applicable).